Products billed under this code include Hydrocortisone Sodium Succinate, Solu-Cortef.
Payment limit per 100 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Hydrocortisone Sodium Succinate | Apotex Corp | 60505-6411-00 | 1 | $23.149 |
| Hydrocortisone Sodium Succinate | Cipla USA, Inc. | 69097-0004-67 | 1 | $23.149 |
| Hydrocortisone Sodium Succinate | Zydus Pharmaceuticals (USA) Inc. | 70710-1907-01 | 1 | $23.149 |
| Solu-Cortef | Pfizer Inc | 00009-0005-01 | 10 | $231.49 |
| Solu-Cortef | Pfizer Inc | 00009-0011-03 | 1 | $23.149 |
| Solu-Cortef | Pfizer Inc | 00009-0011-04 | 25 | $578.725 |
| Solu-Cortef | Pfizer Inc | 00009-0013-05 | 3 | $69.447 |
| Solu-Cortef | Pfizer Inc | 00009-0013-06 | 75 | $1,736.175 |
| Solu-Cortef | Pfizer Inc | 00009-0016-12 | 5 | $115.745 |
| Solu-Cortef | Pfizer Inc | 00009-0825-01 | 1 | $23.149 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Solu-Cortef | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1261-01 | 1 | $23.149 |
| Solu-Cortef | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1262-01 | 3 | $69.447 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $23.149 | +$0.093 | 100 MG | Hydrocortisone sodium succ i | v1, posted September 17, 2026 |
| 3Q26 | $23.056 | +$0.915 | 100 MG | Hydrocortisone sodium succ i | v1, posted September 15, 2026 |
| 2Q26 | $22.141 | +$0.08 | 100 MG | Hydrocortisone sodium succ i | v1, posted September 15, 2026 |
| 1Q26 | $22.061 | +$0.749 | 100 MG | Hydrocortisone sodium succ i | v1, posted September 15, 2026 |
| 4Q25 | $21.312 | +$0.111 | 100 MG | Hydrocortisone sodium succ i | v1, posted September 8, 2026 |
| 3Q25 | $21.201 | +$0.621 | 100 MG | Hydrocortisone sodium succ i | v1, posted March 10, 2026 |
| 2Q25 | $20.58 | −$0.359 | 100 MG | Hydrocortisone sodium succ i | v1, posted March 10, 2026 |
| 1Q25 | $20.939 | +$1.542 | 100 MG | Hydrocortisone sodium succ i | v1, posted December 19, 2025 |
| 4Q24 | $19.397 | −$0.456 | 100 MG | Hydrocortisone sodium succ i | v1, posted June 11, 2025 |
| 3Q24 | $19.853 | +$1.394 | 100 MG | Hydrocortisone sodium succ i | v1, posted June 11, 2025 |
| 2Q24 | $18.459 | +$0.614 | 100 MG | Hydrocortisone sodium succ i | v1, posted March 11, 2025 |
| 1Q24 | $17.845 | +$0.173 | 100 MG | Hydrocortisone sodium succ i | v1, posted December 19, 2024 |
| 4Q23 | $17.672 | +$0.158 | 100 MG | Hydrocortisone sodium succ i | v1, posted October 10, 2024 |
| 3Q23 | $17.514 | −$0.397 | 100 MG | Hydrocortisone sodium succ i | v1, posted June 5, 2024 |
| 2Q23 | $17.911 | +$0.03 | 100 MG | Hydrocortisone sodium succ i | v1, posted February 23, 2024 |
| 1Q23 | $17.881 | +$0.007 | 100 MG | Hydrocortisone sodium succ i | v1, posted December 6, 2023 |
| 4Q22 | $17.874 | +$0.30 | 100 MG | Hydrocortisone sodium succ i | v1, posted June 22, 2023 |
| 3Q22 | $17.574 | +$2.831 | 100 MG | Hydrocortisone sodium succ i | v1, posted June 9, 2023 |
| 2Q22 | $14.743 | −$0.018 | 100 MG | Hydrocortisone sodium succ i | v1, posted December 14, 2022 |
| 1Q22 | $14.761 | −$0.05 | 100 MG | Hydrocortisone sodium succ i | v1, posted June 8, 2022 |
| 4Q21 | $14.811 | +$0.037 | 100 MG | Hydrocortisone sodium succ i | v1, posted June 2, 2022 |
| 3Q21 | $14.774 | +$0.567 | 100 MG | Hydrocortisone sodium succ i | v1, posted June 2, 2022 |
| 2Q21 | $14.207 | +$0.053 | 100 MG | Hydrocortisone sodium succ i | v1, posted March 1, 2022 |
| 1Q21 | $14.154 | – | 100 MG | Hydrocortisone sodium succ i | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
